Active substance
Results for the substance relugolix+estradiol+norethisterone
1 result
About this active substance
The combination of relugolix, estradiol, and norethisterone is used to treat moderate to severe symptoms associated with uterine fibroids (leiomyomas), such as heavy menstrual bleeding, pelvic pain, and anemia. This combination combines a gonadotropin-releasing hormone (GnRH) receptor antagonist (relugolix) with hormones (estradiol and norethisterone) to reduce symptoms and prevent adverse effects associated with estrogen deficiency.
- Relugolix is a GnRH receptor antagonist that reduces the production of estrogen and progesterone by inhibiting the hypothalamic-pituitary-ovarian axis. This leads to a reduction in fibroid size and associated symptoms.
- Estradiol is an estrogen that helps maintain bone density and prevent symptoms of estrogen deficiency, such as hot flashes.
- Norethisterone is a progestin that protects the uterine lining (endometrium) from the adverse effects of estradiol.
This combination is taken orally, usually once daily, and is indicated for limited-term use, typically up to 24 months, due to the risk of bone density loss.
Common side effects include hot flashes, headaches, nausea, fatigue, and irregular menstrual bleeding. Rarely, more serious reactions such as venous thromboembolism, high blood pressure, or liver dysfunction may occur. Regular monitoring of bone density and other potential adverse effects is essential during treatment.
Treatment with this combination should be administered under the supervision of a doctor, and patients must strictly follow the prescribed duration and dosage.
- Relugolix is a GnRH receptor antagonist that reduces the production of estrogen and progesterone by inhibiting the hypothalamic-pituitary-ovarian axis. This leads to a reduction in fibroid size and associated symptoms.
- Estradiol is an estrogen that helps maintain bone density and prevent symptoms of estrogen deficiency, such as hot flashes.
- Norethisterone is a progestin that protects the uterine lining (endometrium) from the adverse effects of estradiol.
This combination is taken orally, usually once daily, and is indicated for limited-term use, typically up to 24 months, due to the risk of bone density loss.
Common side effects include hot flashes, headaches, nausea, fatigue, and irregular menstrual bleeding. Rarely, more serious reactions such as venous thromboembolism, high blood pressure, or liver dysfunction may occur. Regular monitoring of bone density and other potential adverse effects is essential during treatment.
Treatment with this combination should be administered under the supervision of a doctor, and patients must strictly follow the prescribed duration and dosage.